Biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) stated on Wednesday its Non-GAAP net income of USD38.4m for the full year ended 31 December 2018.
This is a growth when compared with a Non-GAAP net loss of USD3.4m for the full year 2017.
Total revenues of USD193.118m were collected for the full year ended 31 December 2018, up from total revenues of USD165.08m for the full year 2017.
For the full year 2019, the company anticipates total revenues in the USD215m and USD225m range.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government